Liminatus Pharma Inc. (LIMN) vs Xenetic Biosciences, Inc. (XBIO)

Liminatus Pharma Inc. and Xenetic Biosciences, Inc. are both Biotechnology companies. Liminatus Pharma Inc. and Xenetic Biosciences, Inc. are of similar size ($5.8M and $5.6M). Liminatus Pharma Inc. has the higher net margin (0.00% vs −75.9%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Xenetic Biosciences, Inc. leads on 7 and Liminatus Pharma Inc. on 5.

Valuation

Metric LIMN XBIO Biotechnology median
P/E n/m n/m 7.88
P/S n/m 1.67 11.47
P/B 13.53 0.90 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m 0.39 0.74
EV/Sales n/m (0.31) 10.73
Earnings yield (559.52%) (48.95%) (28.84%)
Free cash flow yield (97.71%) (42.50%) (23.03%)

Profitability

Metric LIMN XBIO Biotechnology median
Gross margin — 100.00% 65.16%
Operating margin 0.00% (81.01%) 0.00%
Net margin 0.00% (75.90%) 0.00%
Free cash flow margin 0.00% (70.93%) 0.00%
Return on equity 294.43% (47.05%) (57.72%)
Return on assets (471.47%) (40.17%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric LIMN XBIO Biotechnology median
Revenue growth (TTM) — 33.30% 5.64%
EPS growth (last fiscal year) (112.19%) 38.52% —
Revenue growth, 5-year CAGR — 46.78% 8.40%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric LIMN XBIO Biotechnology median
Debt to equity 4.80 0.00 0.00
Current ratio 1.12 7.43 4.73
Net debt to EBITDA (0.37) 2.78 0.96

Dividend

Metric LIMN XBIO Biotechnology median
Dividend yield — — 2.10%
Payout ratio — 0.00 0.00

Size

Metric LIMN XBIO Biotechnology median
Market cap 5.61m 5.79m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack